---
id: "contrarian-institutional-model-flaw"
type: "contrarian-insight"
source_timestamps: ["§ The Rise of Chinese Competition", "¶7", "¶8"]
tags: ["institutional-economics", "policy", "contrarian-insight"]
related: ["concept-amc-innovators-dilemma", "concept-china-pharma-ascendance"]
challenges: "The conventional U.S. narrative that fixing FDA regulations and increasing NIH funding is sufficient to maintain global biotech leadership."
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Contrarian: Institutions, Not Just Policies, Drive the Innovation Gap

**Contrarian insight.** It is common in the U.S. to blame **regulatory bottlenecks (FDA)** or **lack of federal funding** for slowing innovation. The authors assert instead that **"the pace of innovation ultimately depends on institutions."** They argue China is winning not merely because of state funding or [[entity-nmpa]] reforms, but because Chinese medical institutions have embraced a **fundamentally superior business model prioritizing operational efficiency** (see [[concept-china-pharma-ascendance]]) — which is why the U.S. answer is institutional reinvention ([[concept-amc-innovators-dilemma]]) rather than policy tweaks alone.

**What it challenges:** the conventional U.S. narrative that fixing FDA regulations and increasing NIH funding is **sufficient** to maintain global biotech leadership.

**Counter-perspective (enrichment):** other interpretations stress **population scale, infrastructure investment, and regulatory centralization** over a universally transferable "better" model — i.e., China's rise may be less about one superior institutional model than about scale and coordination.


## Related across articles
- [[contrarian-export-controls-catalyzed]]